Filtered By:
Management: National Institutes of Health (NIH)
Countries: Canada Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 23 results found since Jan 2013.
Folate deficiency increases the incidence of dolutegravir-associated foetal defects in a mouse pregnancy model
EBioMedicine. 2023 Aug 14;95:104762. doi: 10.1016/j.ebiom.2023.104762. Online ahead of print.ABSTRACTBACKGROUND: Dolutegravir (DTG) is a recommended first-line regimen for all people with Human Immunodeficiency Virus (HIV) infection. Initial findings from Botswana, a country with no folate fortification program, showed an elevated prevalence of neural tube defects (NTDs) with peri-conceptional exposure to DTG. Here we explore whether a low folate diet influences the risk of DTG-associated foetal anomalies in a mouse model.METHODS: C57BL/6 mice fed a folate-deficient diet for 2 weeks, were mated and then randomly allocated ...
Source: Cancer Control - August 16, 2023 Category: Cancer & Oncology Authors: Haneesha Mohan Jessica Nguyen Ben MacKenzie Audrey Yee Evelyn Yukino Laurette Tanvi Sanghvi Oscar Tejada Valeriya Dontsova Kit-Yi Leung Cameron Goddard Taylor De Young John G Sled Nicholas D E Greene Andrew J Copp Lena Serghides Source Type: research
The improving Medication Adherence in Adolescents and young adults following Liver Transplantation (iMALT) multisite trial: Design and trial implementation considerations
DISCUSSION: Improving Medication Adherence in adolescent Liver Transplant includes several innovative design elements. The use of a validated, objective adherence index to survey a large cohort of transplant recipients allows the teams to avoid bias inherent in both convenience sampling and referral-based recruitment and enroll only patients whose computed index indicates substantially increased risk of rejection. The remote intervention paradigm helps to engage patients who are by definition hard to engage. The use of an objective, masked medical (rather than behavioral) outcome measure reduces the likelihood of biases re...
Source: Clinical Trials - June 3, 2023 Category: Research Authors: Eyal Shemesh Sarah Duncan-Park George Mazariegos Rachel Annunziato Ravinder Anand Miguel Reyes-Mugica Jeff Mitchell Benjamin L Shneider for iMALT Source Type: research
Second Phase of the NIH Preprint Pilot Launched
Today, we are pleased to announce the launch of the second phase of the NIH Preprint Pilot with the addition of more than 700 new preprint records to PubMed Central (PMC) and PubMed. This second phase expands the scope of the Pilot to include preprints resulting from all NIH-funded research. Eligible preprints are those acknowledging direct support of an NIH award or authored by NIH staff and posted to bioRxiv, medRxiv, arXiv, or Research Square, on or after January 1, 2023. NLM will automatically include the full text of the preprint (as license terms allow) and associated citation information in PMC and PubMed, respectiv...
Source: PubMed Central News - January 30, 2023 Category: Databases & Libraries Source Type: news
Next Phase of NIH Preprint Pilot Launching Soon
Last month, the National Library of Medicine (NLM)announced plans to extend its NIH Preprint Pilot in PubMed Central (PMC) and PubMed beyond COVID-19 to encompass all preprints reporting on NIH-funded research. The second phase of the pilot, launching later this month, will include preprints supported by an NIH award, contract, or intramural program and posted to aneligible preprint server on or after January 1, 2023.In preparation for the launch of this second phase, we have updated PMC and PubMed site features to help users of these databases incorporate the increased volume of preprints into their discovery workflows. S...
Source: PubMed Central News - January 10, 2023 Category: Databases & Libraries Source Type: news
Eleven science stories likely to make big news in 2023
As the COVID-19 pandemic enters its fourth year as a global health emergency, researchers will continue pushing to help make the disease manageable and ordinary. They will track hundreds of subvariants of Omicron, the highly transmissible but seemingly less lethal strain of SARSCoV-2 that dominated in 2022. Virologists will watch the virus’ evolution this year to see whether it has finally slowed or a more dangerous variant pops up, evading much of the immunity that humanity has built up to previous ones. Vaccine researchers hope to develop new shots that provide broad protection against a variety of coronaviruses. Ano...
Source: ScienceNOW - January 4, 2023 Category: Science Source Type: news
Gender disparity among ophthalmologists awarded Canadian institute of health research grants
Women Health. 2023 Jan 2:1-7. doi: 10.1080/03630242.2022.2164113. Online ahead of print.ABSTRACTDespite efforts toward equity, diversity, and inclusion in academic ophthalmology faculties, gender disparity continues to exist. Current evidence indicates that female ophthalmologists consistently hold lower academic ranks and receive less funding from the National Institutes of Health compared to their male colleagues. The extent of this disparity is unknown in the Canadian context. We sought to characterize the gender gap in Canadian Institutes of Health Research funding among ophthalmologists. From inception, funding decisi...
Source: Women and Health - January 2, 2023 Category: Primary Care Authors: Chi-Wei Tien Brendan Tao Faisal Khosa Source Type: research
New TREMFYA ® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with moderately to severely active ulcerative colitis (UC) with inadequate responses to previous treatments. The data presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting show an overall clinical response rate of approximately 80 percent in patients who were randomized to TREMFYA® (guselkumab).Clinical responsea at weeks 12 or 24 of the study was ultimately achieved by 80.2 percent of patients who w...
Source: Johnson and Johnson - October 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
Fidelity Protocol Development for a Telehealth Type 1 Diabetes Occupation-Based Coaching Intervention
Can J Occup Ther. 2022 Feb 21:84174221078644. doi: 10.1177/00084174221078644. Online ahead of print.ABSTRACTBackground. Preserving fidelity ascertains that the intervention is delivered as intended in occupational therapy (OT) contexts. The process of conceptualizing and developing fidelity standards, however, is seldom documented in the existing literature. Purpose. The purpose of this methodological description paper was to (a) describe the process of generating a comprehensive fidelity plan based on the National Institutes of Health Behavioral Change Consortium's five-domain fidelity framework and (b) evaluate the devel...
Source: Canadian Journal of Occupational Therapy - February 21, 2022 Category: Occupational Health Authors: Julia Shin Vanessa D Jewell Amy A Abbott Marion Russell Kathryn Carlson Madison Gordon Source Type: research
